B-ALL
Clinical trials for B-ALL explained in plain language.
Never miss a new study
Get alerted when new B-ALL trials appear
Sign up with your email to follow new studies for B-ALL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental cell therapy takes on tough leukemia
Disease control Recruiting nowThis early-phase trial tests a new treatment called TSLPR-CART for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified in a lab to target a protein called TSLPR found on …
Matched conditions: B-ALL
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New CAR T-Cell booster aims to stop leukemia relapse
Disease control Recruiting nowThis study tests whether a second type of CAR T-cell therapy, targeting CD22, can extend remission in people with B-cell acute lymphoblastic leukemia who have no signs of cancer after initial CD19 CAR T-cell treatment. About 20 children, adolescents, and adults will receive the m…
Matched conditions: B-ALL
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New Dual-Target CAR T-Cell therapy aims to beat relapsed childhood cancers
Disease control Recruiting nowThis study tests a new type of CAR T-cell therapy that targets two proteins, CD19 and CD22, on cancer cells. It is for children and young adults aged 3 to 39 with B-cell cancers like leukemia or lymphoma that have not been cured by standard treatments. Participants receive their …
Matched conditions: B-ALL
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New gene therapy injection shows promise for tough leukemia
Disease control Recruiting nowThis early-phase trial is testing a new gene therapy called KSV01 for patients with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatment. The study will enroll 30 adults aged 18 to 80 to check if the treatment is safe and tolerable, and to…
Matched conditions: B-ALL
Phase 1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Engineered immune cells take aim at childhood leukemia in new trial
Disease control Recruiting nowThis early-phase trial tests a new treatment called CD123-CAR T cells for children and young adults (up to age 21) with certain types of leukemia or related blood cancers that have come back or not responded to standard therapy. The treatment involves collecting the patient's own…
Matched conditions: B-ALL
Phase 1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
CAR-T cells take on stubborn leukemia after transplant in new trial
Disease control Recruiting nowThis study compares two treatments for patients with B-cell acute lymphoblastic leukemia who still have small amounts of cancer cells (minimal residual disease) after a stem cell transplant. One group receives a single infusion of their own genetically modified immune cells (CAR-…
Matched conditions: B-ALL
Phase 3 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo therapy aims to boost CAR t-cell success in hard-to-treat blood cancers
Disease control Recruiting nowThis early-phase study tests a radioactive drug (131-I apamistamab) given before CAR T-cell therapy for people with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma. The goal is to find a safe dose and see if the combination is tolera…
Matched conditions: B-ALL
Early phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New CAR-T therapy aims to tackle tough childhood leukemia
Disease control Recruiting nowThis phase 2 trial tests a new treatment called Senl_B19 CAR-T cells for people aged 3 to 25 with B-cell acute lymphoblastic leukemia that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to target and kill cancer cel…
Matched conditions: B-ALL
Phase 2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Smart testing after CAR t: could it spare kids from unneeded transplants?
Knowledge-focused Recruiting nowThis study tests whether regular blood and bone marrow tests using advanced DNA sequencing can better monitor children with B-cell acute lymphoblastic leukemia (B-ALL) after they achieve remission with CAR T therapy. The goal is to see if these tests can identify who is truly cur…
Matched conditions: B-ALL
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 21, 2026 13:00 UTC
-
New study tracks hidden dangers of CAR t therapy in kids
Knowledge-focused Recruiting nowThis study follows 100 children and young adults who received CAR T cell therapy to understand short- and long-term side effects like infections, slow blood cell recovery, and nerve problems. Researchers will check participants at 3, 6, 12, and 24 months after treatment. The goal…
Matched conditions: B-ALL
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC